# A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia

> **NCT04409262** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 649 (actual)

## Conditions studied

- COVID-19 Pneumonia

## Interventions

- **DRUG:** Remdesivir
- **DRUG:** Tocilizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04409262
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-16
- **Primary completion:** 2021-02-01
- **Final completion:** 2021-03-08
- **Target enrollment:** 649 (ACTUAL)
- **Last updated:** 2022-02-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04409262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04409262, "A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04409262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*